NEW YORK–(BUSINESS WIRE)–Orbsen Therapeutics (www.orbsentherapeutics.com) breakthrough stromal cell immunotherapy, OBRCEL-M™, developed as part of NEPHSTROM, a European Union Horizon 2020-funded research project coordinated by NUI Galway, has been approved to begin testing in a randomised, double blind, and placebo-controlled European clinical trial to treat diabetic kidney disease. […]

Dr. Jack Kavanaugh, an internationally recognized surgeon and businessman who has spearheaded the commercialization of cellular therapies and emerging biotechnology firms has been named Chairman of Orbsen Therapeutics, it was announced today by Dr. Chris Coughlan, Founding Director. “Orbsen Therapeutics has developed cutting edge stem cell technology and is poised to become a leader in [...]

8 June 2015: TheJournal.ie: “NUI Galway spin-out company Orbsen Therapeutics used patented technology to discover the stromal cell therapy, which uses cells purified from healthy donor bone marrow. The four-year research project will see some 48 patients taking part in clinical trials in Galway, Belfast, Birmingham and Bergamo to test the treatment.” […]

 8 June, 2015:  The Irish Times covered the kick-off of Nephstrom. "The new €6 million EU-funded project, led by NUIG Regenerative Medicine Institute director Prof Timothy O’Brien, will evaluate a type of “next-generation” cell therapy discovered by researchers at the NUIG campus company Orbsen Therapeutics." Read the complete story at the Irish Times, or learn [...]

The Nephstrom project and the promise of Orbsen’s stromal cell therapy are up for discussion when RegMedNet interviews Remedi Chair (and Orbsen Director), Professor Timothy O’Brien. “Funded by a €6-million grant from the European Union Horizon 2020 programme and including many partners, the project is now setting up a stem cell factory with the NHS [...]

Smartfutures interviews Dr. Steve Elliman, head of research at Orbsen Therapeutics, who says no two days are the same at his Galway start-up. Describe your typical day My chief function is to manage 11 research scientists in the lab. Another role is grant writing. We’re a start-up so we don’t [...]

Pictured L to R: Professor Tim O’Brien, Brian Molloy and Dr Stephen Elliman of Orbsen Therapeutics. Monday, 12 May 2014 Orbsen Therapeutics’ proprietary stromal cell therapy (Cyndacel-M™) has been selected to be tested in a EU Framework 7 (FP7) funded safety trial for the treatment of non-healing, ulcerating wounds in [...]

12 June, 2014: The Minister for Jobs, Enterprise and Innovation, Richard Bruton TD, this week announced the award of funding of over €1.7 million to support twenty new industry-academia partnerships through the Science Foundation Ireland Industry Fellowship Programme, including Dr Daniel O’Toole’s work on the development of a regulatory compliant cell product for Acute [...]